58 related articles for article (PubMed ID: 21047593)
1. Lead-time in the European Randomised Study of Screening for Prostate Cancer.
Finne P; Fallah M; Hakama M; Ciatto S; Hugosson J; de Koning H; Moss S; Nelen V; Auvinen A
Eur J Cancer; 2010 Nov; 46(17):3102-8. PubMed ID: 21047593
[TBL] [Abstract][Full Text] [Related]
2. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
3. Prediagnostic Prostate-specific Antigen Testing and Clinical Characteristics in Men with Lethal Prostate Cancer.
Arvendell M; Björnebo L; Eklund M; Giovanni Falagario U; Chandra Engel J; Akre O; Grönberg H; Nordström T; Lantz A
Eur Urol Open Sci; 2024 Apr; 62():61-67. PubMed ID: 38468863
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Age, Age at Death and Stage Migration in Men Dying with or from Prostate Cancer in Denmark.
Andersen MCM; Stroomberg HV; Brasso K; Helgstrand JT; Røder A
Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626426
[TBL] [Abstract][Full Text] [Related]
5. Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study.
Parker J; Crawley D; Garmo H; Lindahl B; Styrke J; Adolfsson J; Lambe M; Stattin P; Van Hemelrijck M; Beckmann K
Front Oncol; 2020; 10():571838. PubMed ID: 33134172
[TBL] [Abstract][Full Text] [Related]
6. The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development.
Fridhammar A; Axelsson U; Persson U; Bjartell A; Borrebaeck CAK
Pharmacoecon Open; 2021 Mar; 5(1):77-88. PubMed ID: 32780268
[TBL] [Abstract][Full Text] [Related]
7. Platelet-to-lymphocyte ratio and systemic immune-inflammation index versus circulating prostate cells to predict significant prostate cancer at first biopsy.
Murray NP; Fuentealba C; Salazar A; Reyes E
Turk J Urol; 2020 Mar; 46(2):115-122. PubMed ID: 32053099
[TBL] [Abstract][Full Text] [Related]
8. Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening.
Yang DX; Makarov DV; Gross CP; Yu JB
Cancer Control; 2020; 27(1):1073274820902267. PubMed ID: 32003227
[TBL] [Abstract][Full Text] [Related]
9. An expanded biomarker panel for the detection of prostate cancer from urine DNA.
Brikun I; Nusskern D; Freije D
Exp Hematol Oncol; 2019; 8():13. PubMed ID: 31297302
[TBL] [Abstract][Full Text] [Related]
10. Factors Related to Prostate-Specific Antigen-Based Prostate Cancer Screening in Primary Care: Retrospective Cohort Study of 120,587 French Men Over the Age of 50 Years.
Rat C; Schmeltz H; Rocher S; Nanin F; Gaultier A; Nguyen JM
JMIR Public Health Surveill; 2018 Oct; 4(4):e10352. PubMed ID: 30355559
[TBL] [Abstract][Full Text] [Related]
11. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.
Brikun I; Nusskern D; Decatus A; Harvey E; Li L; Freije D
Clin Epigenetics; 2018; 10():91. PubMed ID: 29988684
[TBL] [Abstract][Full Text] [Related]
12. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
13. Prostate brachytherapy in Ghana: our initial experience.
Mensah JE; Yarney J; Vanderpuye V; Akpakli E; Tagoe S; Sasu E
J Contemp Brachytherapy; 2016 Oct; 8(5):379-385. PubMed ID: 27895678
[TBL] [Abstract][Full Text] [Related]
14. Circulating Folate and Vitamin B
Price AJ; Travis RC; Appleby PN; Albanes D; Barricarte Gurrea A; Bjørge T; Bueno-de-Mesquita HB; Chen C; Donovan J; Gislefoss R; Goodman G; Gunter M; Hamdy FC; Johansson M; King IB; Kühn T; Männistö S; Martin RM; Meyer K; Neal DE; Neuhouser ML; Nygård O; Stattin P; Tell GS; Trichopoulou A; Tumino R; Ueland PM; Ulvik A; de Vogel S; Vollset SE; Weinstein SJ; Key TJ; Allen NE;
Eur Urol; 2016 Dec; 70(6):941-951. PubMed ID: 27061263
[TBL] [Abstract][Full Text] [Related]
15. A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk.
Travis RC; Appleby PN; Martin RM; Holly JMP; Albanes D; Black A; Bueno-de-Mesquita HBA; Chan JM; Chen C; Chirlaque MD; Cook MB; Deschasaux M; Donovan JL; Ferrucci L; Galan P; Giles GG; Giovannucci EL; Gunter MJ; Habel LA; Hamdy FC; Helzlsouer KJ; Hercberg S; Hoover RN; Janssen JAMJL; Kaaks R; Kubo T; Le Marchand L; Metter EJ; Mikami K; Morris JK; Neal DE; Neuhouser ML; Ozasa K; Palli D; Platz EA; Pollak M; Price AJ; Roobol MJ; Schaefer C; Schenk JM; Severi G; Stampfer MJ; Stattin P; Tamakoshi A; Tangen CM; Touvier M; Wald NJ; Weiss NS; Ziegler RG; Key TJ; Allen NE
Cancer Res; 2016 Apr; 76(8):2288-2300. PubMed ID: 26921328
[TBL] [Abstract][Full Text] [Related]
16. Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies.
Key TJ; Appleby PN; Travis RC; Albanes D; Alberg AJ; Barricarte A; Black A; Boeing H; Bueno-de-Mesquita HB; Chan JM; Chen C; Cook MB; Donovan JL; Galan P; Gilbert R; Giles GG; Giovannucci E; Goodman GE; Goodman PJ; Gunter MJ; Hamdy FC; Heliövaara M; Helzlsouer KJ; Henderson BE; Hercberg S; Hoffman-Bolton J; Hoover RN; Johansson M; Khaw KT; King IB; Knekt P; Kolonel LN; Le Marchand L; Männistö S; Martin RM; Meyer HE; Mondul AM; Moy KA; Neal DE; Neuhouser ML; Palli D; Platz EA; Pouchieu C; Rissanen H; Schenk JM; Severi G; Stampfer MJ; Tjønneland A; Touvier M; Trichopoulou A; Weinstein SJ; Ziegler RG; Zhou CK; Allen NE;
Am J Clin Nutr; 2015 Nov; 102(5):1142-57. PubMed ID: 26447150
[TBL] [Abstract][Full Text] [Related]
17. Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.
Pashayan N; Duffy SW; Neal DE; Hamdy FC; Donovan JL; Martin RM; Harrington P; Benlloch S; Amin Al Olama A; Shah M; Kote-Jarai Z; Easton DF; Eeles R; Pharoah PD
Genet Med; 2015 Oct; 17(10):789-95. PubMed ID: 25569441
[TBL] [Abstract][Full Text] [Related]
18. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era.
Jahn JL; Giovannucci EL; Stampfer MJ
Int J Cancer; 2015 Dec; 137(12):2795-802. PubMed ID: 25557753
[TBL] [Abstract][Full Text] [Related]
19. Overdiagnosis and overtreatment of prostate cancer.
Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
[TBL] [Abstract][Full Text] [Related]
20. Gleason grade progression is uncommon.
Penney KL; Stampfer MJ; Jahn JL; Sinnott JA; Flavin R; Rider JR; Finn S; Giovannucci E; Sesso HD; Loda M; Mucci LA; Fiorentino M
Cancer Res; 2013 Aug; 73(16):5163-8. PubMed ID: 23946472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
